Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.48 – $0.55
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.7M | $13.5M | $310.3M | $110.0M | $21.0M | $11.6M | $19.6M | $20.4M |
| Cost of revenue | $4.6M | $4.0M | $73.5M | $78.6M | $15.3M | $7.8M | −$12.4M | $12.5M |
| Gross profit | $7.6M | $7.2M | $236.5M | $35.3M | $5.7M | $3.7M | $32.1M | $7.9M |
| Gross margin | 55.3% | 52.8% | 76.2% | 32.1% | 27.3% | 32.2% | 163.4% | 38.7% |
| R&D | $406.3K | $385.3K | $1.8M | $5.7M | $5.0M | $3.2M | $2.8M | $4.2M |
| Operating income | −$308.3K | −$1.8M | $187.4M | −$4.7M | −$15.7M | −$29.5M | −$37.3M | −$13.2M |
| EBITDA | −$255.0K | −$991.6K | $187.0M | $45.8M | −$11.7M | −$18.2M | −$31.4M | −$8.2M |
| Net income | −$4.3M | −$6.8M | $148.2M | −$9.7M | −$25.7M | −$28.3M | −$41.8M | −$23.3M |
| Net margin | -31.1% | -50.1% | 47.8% | -8.8% | -122.3% | -244.3% | -212.7% | -114.2% |
| EPS (diluted) | -0.12 | -0.14 | 2.16 | -0.16 | -0.31 | -0.40 | -0.59 | -0.33 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $26M | $-0.12 | $-0.12–$-0.12 | 1 |
| 2027 | $29M | $-0.07 | $-0.07–$-0.07 | 1 |
Forward consensus · source: Financial Modeling Prep
NOVACYT CLAMART
No one on the platform currently holds NVYTF.
No tracked institution reports a position in NVYTF as of their last filing.
No one on the platform has traded NVYTF yet.
| $10M |
| — |
| ITHUFiAnthus Capital Holdings, Inc. | $0.01 | +12.36% | $35M | — |
| MDDVFMedical Developments International Limited | $0.37 | +0.00% | $42M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 1.5× sales vs its 3.7× historical median P/S.
Fair value ≈ $1.14 · price $0.48 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.